BALOVAPTAN

Balovaptan is a vasopressin V1a receptor antagonist studied for social behavior modulation in autism spectrum disorder. Side effects include headache, fatigue, insomnia, and GI discomfort.

Product Description


Mechanism of Action

BALOVAPTAN (ID 28877) demonstrates a high‑dimensional biochemical activity framework integrating catalytic‑domain modulation, multi‑axis signalling interference, mitochondrial‑network recalibration, redox‑equilibrium restructuring, ion‑flux redistribution, membrane‑potential modulation, cytoskeletal‑architecture remodelling and transcription‑factor circuit reprogramming. The compound’s molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotide‑binding pockets, redox‑buffer matrices and polymeric scaffolding complexes—enabling influence across metabolic, genomic, structural and electrophysiological systems.

BALOVAPTAN may alter phosphorylation‑flow geometry across ERK, MAPK, JNK, p38 and PI3K–AKT axes; reconfigure G‑protein signal‑state logic; redistribute Ca²⁺ microdomains; adjust IP₃/DAG signalling topology; and recalibrate cAMP–PKA amplitude. Mitochondrial effects include ETC‑complex rebalancing, ATP/ADP flux modulation, ROS‑threshold displacement, membrane‑potential polarity shifting, and ER–mitochondria stress‑signal cross‑talk integration.

High‑Precision Research Applications

  • Kinome‑scale interference mapping & catalytic‑cascade modelling
  • High‑resolution molecular docking & conformational‑transition prediction
  • UPR/ER‑stress, mitophagy & autophagic‑flux regulatory modelling
  • Multi‑omics network reconstruction: RNA‑seq, metabolomics, proteomics, phosphoproteomics
  • Cytoskeletal tension‑mapping & polymer‑turnover analytics
  • Advanced cell‑fate pathway modelling (apoptosis, necroptosis, ferroptosis, parthanatos)
  • AI‑driven SAR/QSAR predictive compound‑performance optimisation

Toxicodynamics & Hazard Spectrum

  • Rapid ROS escalation & antioxidant‑buffer collapse
  • Mitochondrial fragmentation or ETC‑axis suppression
  • Severe Na⁺/K⁺/Ca²⁺ ionic‑flux destabilisation
  • Cytoskeletal depolymerisation & membrane‑integrity loss
  • Inflammatory hyperactivation (NF‑κB, STAT, IRF signalling clusters)
  • Activation of multi‑axis programmed‑cell‑death pathways
  • Epigenetic drift including methylation/acetylation instability

For expert laboratory use only — not intended for biological or therapeutic exposure.

Datasheet


Molecular Formula

C27H29ClN4O2

Molecular Weight

409.9 g/mol

CAS Number

1228088-30-9

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Balovaptan; 1228088-30-9; RG7314; RO5285119; Balovaptan [INN]

IUPAC/Chemical Name

8-chloro-5-methyl-1-(4-pyridin-2-yloxycyclohexyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine

InChl Key

GMPZPHGHNDMRKL-UHFFFAOYSA-N

InChl Code

InChI=1S/C22H24ClN5O/c1-27-13-16-12-17(23)7-10-19(16)28-20(14-27)25-26-22(28)15-5-8-18(9-6-15)29-21-4-2-3-11-24-21/h2-4,7,10-12,15,18H,5-6,8-9,13-14H2,1H3

References

https://pubchem.ncbi.nlm.nih.gov/compound/46200932;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download